A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists ...

The growing popularity of GLP-1 agonists for weight management has sparked a surge in alternative dosing methods, particularly microdosing of Ozempic. This emerging practice involves intentionally ...

Incretin mimetics are revolutionizing obesity treatment, but high prices and supply shortages limit patient access. Some clinicians have suggested less frequent dosing as an off-ramping strategy to ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs ... Some pens are single-use and contain a premeasured dose of the GLP-1 RA. In other cases, you select the amount of medication to be injected.

But if you are already taking insulin, you may be able to decrease your dose (or maybe stop it completely) if taking a GLP-1 agonist is effective, Neumiller says. Work with your healthcare team to ...

today announced interim results from the ongoing Phase 2 COURAGE trial investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin ...

In GLP-1 receptor agonist-naive patients starting the generic liraglutide, once daily, adherence may not be a concern. However, for people who may switch from a once-weekly to a once-daily dosing ...

The small-scale, 28-day study saw 36 healthy adults with obesity or overweight receive one of three oral doses of the GLP-1 agonist ... 740 mg, dose of TERN-601 saw a placebo-adjusted mean ...

They also highlight the need for future clinical trials to more conclusively determine the dose and duration of GLP-1 receptor agonist-based treatments in patients addicted to different types of ...

whereas others used daily dosing or continuous infusions. Most studies included MACE as the primary cardiovascular outcome, whereas kidney outcomes varied across studies. GLP-1 receptor agonists ...